Sirnaomics Inc., a Gaithersburg, Maryland, USA-based biopharmaceutical company in discovery and development of RNAi therapeutics, raised USD$105m in Series D financing.
The round was co-led by existing investor Rotating Boulder Fund, new investor Walvax Biotechnology Co., Ltd. and Sunshine Riverhead Capital, with support from existing investors Sangel Capital and new investors: Longmen Capital, HongTao Capital and Alpha Win Capital.
Proceeds for the financing will be used to fund continued development of its novel RNAi therapeutics for treatment of diverse human disorders, including cancers, fibrosis diseases, metabolic diseases and viral infections.
Led by Patrick Lu, PhD, Founder, President and CEO, Sirnaomics is a biopharmaceutical company for discovery and development of RNAi therapeutics, with subsidiaries in Suzhou and Guangzhou, China. Its mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The therapeutic areas of focus include oncology, anti-fibrotic therapeutics and viral infection.
Sirnaomics will build on the positive results from its recent Phase IIa study for treatment of Cutaneous Squamous Cell Carcinoma in-situ (April 9, 2020 news release), and conduct multiple clinical studies to further evaluate its lead product candidates, STP705 and STP707, which are dual targeting siRNA therapeutics against TGF-β1 and COX-2 for both local and systemic administrations to treat various types of cancers and fibrotic diseases. A clinical focus will be immune oncological evaluation for these dual-targeted siRNA inhibitors, based on potential synergistic effects with immune checkpoint inhibitors observed at both preclinical and clinical settings.